Join the Oncology Voice Network. Join for Free
Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)
COVID-19 impact on medical publishing virtual congresses and conferences challenges in medical publications pandemic effect on scientific journals

Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)


Share This Article


Summary

The Coronavirus (COVID-19) pandemic has impacted nearly every facet of our personal and professional lives. Medical publication professionals are facing uncharted territory and uncertainty as to how long the impact will last.

With live congresses being canceled, postponed or transitioned to a virtual format, we must now make decisions to convert presentations to virtual format, ensure embargo and copyright policies are followed, and actively update publication plans. Publications may face delays because authors and peer reviewers are focusing on clinical care, and also because of data availability delays.

Please join us to hear a panel of experts discuss their experiences and views, review our membership survey results, and present case studies to help guide professionals through this unprecedented situation.

At the end of this session, participants should be able to:

  • Be knowledgeable of challenges to medical publishing stemming from the Coronavirus (COVID-19) pandemic
  • Be aware of how congresses and journal publishers are being affected
  • Modify publication plans appropriately in response to changing conditions
  • Maintain good publication practices and ethics in a rapidly shifting environment

Click for Source Download PDF version
COVID-19 impact on medical publishing, virtual congresses and conferences, challenges in medical publications, pandemic effect on scientific journals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN